Corporate Profile for Beacon Diagnostics, Inc., dated Dec. 6, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services. These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-
Published Date: Dec. 6, 1996
Company Name: Beacon Diagnostics, Inc.
Address: 366-B Lakeside Dr.
Foster City, Calif. 94404
Main Telephone
Number: 415/574-4800
Chief Executive
Officer: Jerome Mattingly, Ph.D.
Chief Financial
Officer: John Supan, CPA
Public Relations
Contact: Bert Del Villano, PhD
Business number: 415/574-4800
Industry: Biotechnology
Company description: Beacon Diagnostics, Inc. develops, manufactures and markets diagnostic products using platform technologies that enable the rapid detection of antibodies and antigens in noninvasive specimens (i.e., saliva, urine, etc.). The company's lead product, OraScreen(TM) HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. Rapid Test, is a simple, multi-step dipstick dipstick /dip·stick/ (dip´stik) a strip of cellulose chemically impregnated to render it sensitive to protein, glucose, or other substances in the urine. system for detection of antibodies to HIV in saliva. The test can be performed in the physician's office or at home in 15 minutes, without the need for technical training, instruments or a laboratory. Beacon has already begun production for international distribution and expects to file an investigational device exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and (IDE) with the Food and Drug Administration in early 1997 to begin clinical trials in the U.S. The company is also developing other innovative point-of-care technologies for use in additional rapid saliva tests for hepatitis and gastrointestinal, prostate, ovarian and breast cancers. Beacon was formed in 1991 and immediately obtained exclusive worldwide rights to certain technologies that emerged from research programs at the University of Florida University of Florida is the third-largest university in the United States, with 50,912 students (as of Fall 2006) and has the eighth-largest budget (nearly $1.9 billion per year). UF is home to 16 colleges and more than 150 research centers and institutes. . In addition to the OraScreen technology, Beacon acquired a license to LIDA LIDA Linguistic Assistant for Domain Analysis LIDA Learning Intelligent Distribution Agent LIDA List of Inherited Disorders in Animals LIDA Lebanese Investment Development Authority , an homogenous homogenous - homogeneous immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. system for detecting either antibodies or antigens. LIDA is in the research phase of development. Beacon Diagnostics is located in Foster City. The company initially will use contract manufacturers in Singapore and Mexico to produce the OraScreen(TM) HIV Rapid Test for international distribution. The product will be marketed through regional distributors who will be responsible for regulatory approval in their territories. Beacon will market the product in the U.S. upon approval by the Food and Drug Administration. CONTACT: Beacon Diagnostics, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion